Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15310%2F14%3A33144644" target="_blank" >RIV/61989592:15310/14:33144644 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15110/14:33144644

Výsledek na webu

<a href="http://dx.doi.org/10.5507/bp.2013.022" target="_blank" >http://dx.doi.org/10.5507/bp.2013.022</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5507/bp.2013.022" target="_blank" >10.5507/bp.2013.022</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma

Popis výsledku v původním jazyce

Aims: A retrospective analysis of patients with Hodgkin lymphoma (HL) was performed to assess their outcome regarding relative dose intensity (RDI) of chemotherapy administered in primary treatment. Methods: A total of 194 patients were divided into three groups with different RDI of primary chemotherapy (100%, 90-99% and { 90%). Reduced RDI in two groups (90-99% and { 90%) was caused by the delay of the interval between the administration of some chemotherapeutic courses. The probability of complete remission (CR), disease relapse, event-free survival (EFS) and overall survival (OS) as the basic parameters of patient outcome were statistically compared. Results: Multivariate analysis showed here were no significant differences in probability of CR (HR0.9, 95% CI [0.75-1.08], P=0.5), risk of relapse (HR 1.34, 95% CI [0.92-1.94], P=0.11) or death (HR 1.52, 95% CI [0.94-2.5], P=0.13). There were also no significant differences in probability of EFS (mean 13 vs. 10 vs. 12 years, P=0.17;

Název v anglickém jazyce

Reduced relative dose intensity of primary chemotherapy does not influence prognosis of patients with Hodgkin lymphoma

Popis výsledku anglicky

Aims: A retrospective analysis of patients with Hodgkin lymphoma (HL) was performed to assess their outcome regarding relative dose intensity (RDI) of chemotherapy administered in primary treatment. Methods: A total of 194 patients were divided into three groups with different RDI of primary chemotherapy (100%, 90-99% and { 90%). Reduced RDI in two groups (90-99% and { 90%) was caused by the delay of the interval between the administration of some chemotherapeutic courses. The probability of complete remission (CR), disease relapse, event-free survival (EFS) and overall survival (OS) as the basic parameters of patient outcome were statistically compared. Results: Multivariate analysis showed here were no significant differences in probability of CR (HR0.9, 95% CI [0.75-1.08], P=0.5), risk of relapse (HR 1.34, 95% CI [0.92-1.94], P=0.11) or death (HR 1.52, 95% CI [0.94-2.5], P=0.13). There were also no significant differences in probability of EFS (mean 13 vs. 10 vs. 12 years, P=0.17;

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/EE2.3.20.0170" target="_blank" >EE2.3.20.0170: Budování výzkumně-vzdělávacího týmu v oblasti modelování přírodních jevů a využití geoinformačních systémů, s vazbou na zapojení do mezinárodních sítí a programů.</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>Z - Vyzkumny zamer (s odkazem do CEZ)<br>S - Specificky vyzkum na vysokych skolach

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Biomedical Papers-Olomouc

ISSN

1213-8118

e-ISSN

—

Svazek periodika

158

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

428-432

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—